UCB faces U.S. patent challenge for epilepsy drug

May 24 (Reuters) - The U.S. Patent and Trademark Office

(PTO) has begun a trial into whether Belgian pharmaceutical

company UCB's patent for an epilepsy drug is valid,

said a generic drug company that is challenging UCB's claim.

Read more